Midcourse correction to a clinical trial when the event rate is underestimated: The Look AHEAD (Action for Health in Diabetes) Study

Clinical Trials

Volumn 9, Issue 1, 2012, Pages 113-124

  Brancati, Frederick L ^a   Evans, Mary ^b   Furberg, Curt D ^c   Geller, Nancy ^d   Haffner, Steven ^e   Kahn, Steven E ^f   Kaufmann, Peter G ^d   Lewis, Cora E ^g   Nathan, David M ^h   Pitt, Bertram ⁱ   Safford, Monika M ^g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e University of Washington ^*

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LUNG EMBOLISM; MORTALITY; NEOPLASM; OBESITY; PRIORITY JOURNAL; REVASCULARIZATION;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SINGLE-BLIND METHOD;

EID: 84857079880     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511432726     Document Type: Conference Paper

References (29)

1. The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults.2000; NIH Publication No. 00-4084. http://www.nhlbi.nih.gov/guidelines/obesity/prctgd-c.pdf (accessed 6 December 2010).
2. Andersen RE, Wadden TA, Bartlett SJ, et al. Effects of lifestyle activity vs. structured aerobic exercise in obese women: A randomized trial. JAMA. 1999 ; 281 (4). 335-40 (Pubitemid 29061037)
3. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997 ; 157 (6). 657-67
4. Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): Design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003 ; 24 (5). 610-28
5. Rosamond WD, Folsom AR, Chambless LE, Wang CH. Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol. 2001 ; 30: S17 - S22
6. Siscovick DS, Fried L, Mittelmark M, et al. Exercise intensity and subclinical cardiovascular disease in the elderly. The Cardiovascular Health Study. Am J Epidemiol. 1997 ; 145 (11). 977-86 (Pubitemid 27215480)
7. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007 ; 356: 2388-98 (Pubitemid 46883773)
8. Paynter NP, Sharrett AR, Louis TA, et al. Paired comparison of observed and expected coronary heart disease rates over 12 years from the Atherosclerosis Risk in Communities Study. Ann Epidemiol. 2010 ; 20 (9). 683-90
9. Berrington de, Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 ; 363: 2211-19
10. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 ; 348 (17). 1625-38 (Pubitemid 36459468)
11. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: A statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003 ; 108 (20). 2543-9
12. Wittes J. On changing a long-term clinical trial midstream. Stat Med. 2002 ; 21 (19). 2789-95
13. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA. 2004 ; 291 (20). 2457-65 (Pubitemid 38669189)
14. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004 ; 171 (7). 735-40 (Pubitemid 39319090)
15. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA. 2009 ; 302 (9). 977-84
16. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet. 2005 ; 366 (9493). 1279-89 (Pubitemid 41416583)
17. Freemantle N. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?. BMJ. 2005 ; 331 (7520). 836-8 (Pubitemid 41442369)
18. Skyler JS. PROactive: A sad tale of inappropriate analysis and unjustified interpretation. Clin Diabetes. 2006 ; 24 (2). 63-5
19. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005 ; 366 (9500). 1849-61
20. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004 ; 351 (20). 2058-68
21. Califf RM, Boolell M, Haffner SM, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008 ; 156 (4). 623-32
22. Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 ; 362 (16). 1463-76
23. Fox KM. On reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003 ; 362 (9386). 782-8 (Pubitemid 37093919)
24. Evans S. When and how can endpoints be changed after initiation of a randomized clinical trial?. PLoS Clin Trials. 2007 ; 2 (4). e18
25. Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM. Changing the diagnosis of acute myocardial infarction: Implications for practice and clinical investigations. Am Heart J. 2002 ; 144 (6). 957-80 (Pubitemid 36026909)
26. Lim E, Brown A, Helmy A, Mussa S, Altman DG. Composite outcomes in cardiovascular research: A survey of randomized trials. Ann Intern Med. 2008 ; 149 (9). 612-17
27. McCallum RW, Fisher M. Review: Comparing cardiovascular outcomes in diabetes studies. Br J Diabetes Vasc Dis. 2006 ; 6: 111-18 (Pubitemid 44056840)
28. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvistatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 ; 377: 2181-92
29. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowring with atorvastatin in patients with stable coronary artery disease. N Engl J Med. 2005 ; 352: 1425-32